Haematologica
Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.
Mengyao Yuan, Li Zhou, Weiming Li, Xin Du, Jianyu Weng, Linhua Yang, Yanping Ma, Bingcheng Liu, Zhenfang Liu, Qin Wen, Shasha Zhao, Yanli Zhang, Qingxian Bai, Xianqi Feng, Yanqiu Han
Published: 202510.3324/haematol.2025.288249
Abstract
We studied 130 consecutive subjects who presented with (n = 29) or transformed to (n = 101) accelerated phase chronic myeloid leukemia (CML) and who received olverembatinib. 62 were in 2nd chronic phase. All failed ≥ 1 tyrosine kinase-inhibitors (TKI…
Preview only. Read the full abstract at the source